The frequent expression of PDL1 and the very favorable clinical course of one patient who received maintenance immune therapy point to the clinical relevance of recognizing this unusual presentation of NSCLC which is otherwise considered a rapidly fatal disease. This evidence concerns the gene CD274 and non-small cell lung carcinoma.